NZ730924A - Dosage regimen for pegylated interferon - Google Patents
Dosage regimen for pegylated interferonInfo
- Publication number
- NZ730924A NZ730924A NZ730924A NZ73092415A NZ730924A NZ 730924 A NZ730924 A NZ 730924A NZ 730924 A NZ730924 A NZ 730924A NZ 73092415 A NZ73092415 A NZ 73092415A NZ 730924 A NZ730924 A NZ 730924A
- Authority
- NZ
- New Zealand
- Prior art keywords
- interferon
- administered
- period
- treatment period
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192114 | 2014-11-06 | ||
| PCT/US2015/059410 WO2016073825A1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ730924A true NZ730924A (en) | 2022-04-29 |
Family
ID=51945707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ730924A NZ730924A (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7189399B2 (ja) * | 2017-01-18 | 2022-12-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| WO2021216801A1 (en) * | 2020-04-22 | 2021-10-28 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
| AU2022221496A1 (en) * | 2021-08-29 | 2023-03-16 | Pharmaessentia Corporation | Method of Using Pegylated Interferon-alpha |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| RU2002105485A (ru) * | 1999-08-13 | 2004-01-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) |
| HUP0302674A2 (hu) | 1999-08-27 | 2003-11-28 | Maxigen Aps. | Új, béta-interferon-szerű molekulák |
| HRP20020387A2 (en) | 1999-11-12 | 2005-10-31 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| OA13063A (en) | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| EE05509B1 (et) | 2002-01-18 | 2012-02-15 | Biogen@Idec@Ma@Inc | Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid |
| US7345150B2 (en) | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
| AU2003270454B2 (en) | 2002-09-09 | 2010-05-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| MXPA05006945A (es) | 2002-12-26 | 2005-12-14 | Mountain View Pharmaceuticals | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor. |
| JP5048332B2 (ja) | 2003-05-23 | 2012-10-17 | ネクター セラピューティクス | 特定の原子配置を有するポリマー誘導体 |
| CA2547140A1 (en) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| KR20070042567A (ko) | 2004-08-31 | 2007-04-23 | 파마시아 앤드 업존 캄파니 엘엘씨 | 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법 |
| US7365127B2 (en) | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
| EP1869079A2 (en) | 2005-03-11 | 2007-12-26 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101002944B (zh) | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
| EP1834963A1 (en) | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101104078B (zh) | 2006-07-11 | 2011-11-02 | 北京美倍他药物研究有限公司 | 多肽及蛋白药物的聚乙二醇偶合物 |
| CN101108895B (zh) | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| WO2008021487A1 (en) * | 2006-08-18 | 2008-02-21 | Pepgen Corporation | Combination treatment method with interferon-tau |
| CN1966547B (zh) | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
| CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| PT2196475E (pt) | 2007-09-04 | 2012-09-07 | Biosteed Gene Expression Tech Co Ltd | Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação |
| ATE548382T1 (de) * | 2007-09-04 | 2012-03-15 | Biosteed Gene Expression Tech Co Ltd | Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon |
| CN101491682A (zh) | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
| US8273343B2 (en) | 2008-07-31 | 2012-09-25 | Pharmaessentia Corp. | Protein-polymer conjugates |
| CN101671390B (zh) | 2008-09-10 | 2012-10-03 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |
| CN101514229B (zh) | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
| UA109646C2 (uk) | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
| WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
-
2015
- 2015-11-06 NZ NZ730924A patent/NZ730924A/en unknown
- 2015-11-06 ES ES15857703T patent/ES2966888T3/es active Active
- 2015-11-06 WO PCT/US2015/059410 patent/WO2016073825A1/en not_active Ceased
- 2015-11-06 HK HK18102667.8A patent/HK1243627A1/zh unknown
- 2015-11-06 AU AU2015342908A patent/AU2015342908B2/en active Active
- 2015-11-06 EP EP15857703.1A patent/EP3215193B1/en active Active
- 2015-11-06 EA EA201790991A patent/EA037151B1/ru unknown
- 2015-11-06 PT PT158577031T patent/PT3215193T/pt unknown
- 2015-11-06 DK DK15857703.1T patent/DK3215193T3/da active
- 2015-11-06 LT LTEPPCT/US2015/059410T patent/LT3215193T/lt unknown
- 2015-11-06 SI SI201531980T patent/SI3215193T1/sl unknown
- 2015-11-06 US US15/518,423 patent/US11559567B2/en active Active
- 2015-11-06 UA UAA201705540A patent/UA122867C2/uk unknown
- 2015-11-06 PL PL15857703.1T patent/PL3215193T3/pl unknown
- 2015-11-06 CA CA2964390A patent/CA2964390A1/en active Pending
- 2015-11-06 KR KR1020237018405A patent/KR102724837B1/ko active Active
- 2015-11-06 RS RS20231262A patent/RS65015B1/sr unknown
- 2015-11-06 KR KR1020177015233A patent/KR102540109B1/ko active Active
- 2015-11-06 SM SM20240028T patent/SMT202400028T1/it unknown
- 2015-11-06 SG SG11201702798PA patent/SG11201702798PA/en unknown
- 2015-11-06 HR HRP20231732TT patent/HRP20231732T1/hr unknown
- 2015-11-06 TW TW104136693A patent/TWI737583B/zh active
- 2015-11-06 CN CN201580058159.1A patent/CN107530403A/zh active Pending
- 2015-11-06 EP EP23199969.9A patent/EP4282485A3/en active Pending
- 2015-11-06 FI FIEP15857703.1T patent/FI3215193T3/fi active
- 2015-11-06 MY MYPI2017701335A patent/MY191506A/en unknown
- 2015-11-06 HU HUE15857703A patent/HUE064909T2/hu unknown
- 2015-11-06 MX MX2017005244A patent/MX389844B/es unknown
- 2015-11-06 JP JP2017519649A patent/JP6820841B2/ja active Active
- 2015-11-06 PH PH1/2017/500617A patent/PH12017500617B1/en unknown
- 2015-11-06 BR BR112017009193-3A patent/BR112017009193A2/pt not_active Application Discontinuation
-
2017
- 2017-04-06 IL IL251627A patent/IL251627B/en unknown
- 2017-04-18 ZA ZA2017/02704A patent/ZA201702704B/en unknown
- 2017-05-02 CL CL2017001088A patent/CL2017001088A1/es unknown
-
2020
- 2020-09-10 JP JP2020151877A patent/JP2021001184A/ja not_active Withdrawn
-
2022
- 2022-12-23 US US18/088,272 patent/US12343381B2/en active Active
-
2025
- 2025-02-21 US US19/059,883 patent/US20250186552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343381B2 (en) | Dosage regimen for pegylated interferon | |
| TWI272948B (en) | HSA-free stabilized interferon liquid formulations | |
| NO318643B1 (no) | Anvendelse av konsensushumanleukocyttinterferon, eventuelt i kombinasjon med ett eller flere kjemoterapeutiske midler, ved fremstillingen av et medikament for behandling av virussykdommer samtidig som bivirkninger reduseres. | |
| KR101900520B1 (ko) | 복합 조성물 | |
| UA78726C2 (en) | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment | |
| Guilhot et al. | Interferon therapy in chronic myelogenous leukemia | |
| ES2239953T3 (es) | Tratamiento del carcinoma de celulas renales. | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| ES2929379T3 (es) | Métodos para el tratamiento de infecciones por coronavirus | |
| US20170157158A1 (en) | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii | |
| RU2572800C1 (ru) | Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении | |
| ES3009748T3 (en) | Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders | |
| Rodríguez et al. | Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers | |
| ES2275711T3 (es) | Tratamiento de la hepatitis c con timosina, interferon y ribavirina. | |
| ES2243166T3 (es) | Terapia de la leucemia mieloide cronica (cml). | |
| CN114028544A (zh) | 一种动员淋巴瘤和骨髓瘤干细胞的药物组合物 | |
| Hartmann | Feline leukemia virus: still a major cause of death in cats? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2023 BY COMPUTER PACKAGES INC Effective date: 20221017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2024 BY COMPUTER PACKAGES INC Effective date: 20231017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2026 BY IPAN GMBH Effective date: 20251016 |